Related references
Note: Only part of the references are listed.CCN proteins: A centralized communication network
Bernard Perbal
JOURNAL OF CELL COMMUNICATION AND SIGNALING (2013)
High Expression of p300 Has an Unfavorable Impact on Survival in Resectable Esophageal Squamous Cell Carcinoma
Yong Li et al.
ANNALS OF THORACIC SURGERY (2011)
Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets
Joon-Il Jun et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis
W. Glenn McCluggage
PATHOLOGY (2011)
The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory
Robert J. Kurman et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2010)
Molecular characterization of ovarian cancer by gene-expression profiling
C. Gomez-Raposo et al.
GYNECOLOGIC ONCOLOGY (2010)
Cysteine-rich 61 (CYR61) inhibits cisplatin-induced apoptosis in ovarian carcinoma cells
Seung Bae Rho et al.
BIOTECHNOLOGY LETTERS (2009)
Cyr61, a member of ccn (connective tissue growth factor/cysteine-rich 61/nephroblastoma overexpressed) family, predicts survival of patients with endometrial cancer of endometrioid subtype
Hidemichi Watari et al.
GYNECOLOGIC ONCOLOGY (2009)
Functions and mechanisms of action of CCN matricellular proteins
Chih-Chiun Chen et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2009)
Selecting immunohistochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer
Inti Zlobec et al.
JOURNAL OF CLINICAL PATHOLOGY (2007)
The matricellular protein CCN1 is essential for cardiac development
Fan-E Mo et al.
CIRCULATION RESEARCH (2006)
Ovarian carcinomas: CCN genes are aberrantly expressed and CCN1 promotes proliferation of these cells
S Gery et al.
CLINICAL CANCER RESEARCH (2005)
Screening for familial ovarian cancer: Failure of current protocols to detect ovarian cancer at an early stage according to the International Federation of Gynecology and Obstetrics System
D Stirling et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Recent developments in ovarian cancer genetics
GL Barnett et al.
CURRENT OPINION IN OBSTETRICS & GYNECOLOGY (2004)
Cancer of the ovary
SA Cannistra
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Differential expression of the CCN family members Cyr61, CTGF and Nov in human breast cancer
WG Jiang et al.
ENDOCRINE-RELATED CANCER (2004)
Cyr61 suppresses the growth of non-small-cell lung cancer cells via the β-catenin-c-myc-p53 pathway
XJ Tong et al.
ONCOGENE (2004)
Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study
RF Ozols et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
The angiogenic factor CYR61 in breast cancer:: molecular pathology and therapeutic perspectives
JA Menéndez et al.
ENDOCRINE-RELATED CANCER (2003)
Genetic alterations in ovarian carcinoma: with specific reference to histological subtypes
M Fujita et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2003)
CYR61 (CCN1) is essential for placental development and vascular integrity
FE Mo et al.
MOLECULAR AND CELLULAR BIOLOGY (2002)
Cyr61 promotes breast tumorigenesis and cancer progression
MS Tsai et al.
ONCOGENE (2002)
Integrins: Bidirectional, allosteric signaling machines
RO Hynes
CELL (2002)
Escape of p53 protein from E6-mediated degradation in HeLa cells after cisplatin therapy
J Wesierska-Gadek et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Cyr61, a member of CCN family, is a tumor suppressor in non-small cell lung cancer
XJ Tong et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Share Paper
